ROFLU-AD12, NCT07297602: Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study |
|
|
| Recruiting | 2 | 36 | RoW | Oral roflumilast, Roflumilast (generic name), Daxas (brand name in some countries), Roflumilast 500 mcg tablet (formulation identifier) | Nora Mohamed Abdelrazik, Mansoura University Hospital | Atopic Dermatitis | 05/26 | 05/26 | | |
